Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 11/20 | 0.71 |
| ▸ | CNR2 | P34972 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | ALPL | P05186 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6025614 | 0.90 | CNR1 (0.58) | CNR1CNR2 | |
| SCHEMBL6025796 | 0.90 | CNR1 (0.58) | CNR1CNR2RAB9AALPLKMT2A | |
| SCHEMBL6025648 | 0.89 | CNR1 (0.56) | CNR1CNR2ALPL | |
| SCHEMBL6026092 | 0.89 | CNR1 (0.56) | CNR1NPC1RAB9AALPLMEN1 | |
| SCHEMBL6025823 | 0.89 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL6025806 | 0.88 | CNR1 (0.56) | CNR1CNR2 | |
| SCHEMBL6026396 | 0.86 | ALPL (0.54) | CNR1ALPL | |
| SCHEMBL6025602 | 0.86 | CNR1 (0.53) | CNR1CNR2 | |
| SCHEMBL6812212 | 0.86 | SLC6A7 (0.55) | CNR1MEN1KMT2A | |
| SCHEMBL6025637 | 0.85 | CNR1 (0.53) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | claimed |
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259887-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885CNR2 2/4885NPC1 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.